Triple therapy prioritized


The American medicines agency FDA has assigned the Breakthrough Therapy Designation to a combination therapy that has its roots in the Netherlands Cancer Institute. Six years ago René Bernards and colleagues discovered why colon cancer cells are resistant to BRAF inhibitors. This knowledge lies at the root of an international clinical study with promising interim results, based upon which the FDA announces to speed up the approval process of the used drug combination.

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.